Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anlotinib + cisplatin + pemetrexed
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Anlotinib is an oral small molecule multi-target tyrosine kinase inhibitor that inhibits angiogenesis and tumor proliferation by targeting vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), and c-Kit. Cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, inhibiting DNA replication and transcription. Pemetrexed is an antifolate antimetabolite that disrupts folate-dependent metabolic processes essential for cell replication. The combination of these three drugs has been investigated as a first-line regimen for advanced non-squamous non-small cell lung cancer (NSCLC) in patients without EGFR/ALK mutations, showing promising antitumor activity and manageable toxicity[1][2][3].
- Other names
- anlotinib/cisplatin/pemetrexedanlotinib with cisplatin and pemetrexed
02
Targets
GART (GAR transformylase)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR2 (Vascular endothelial growth factor receptor 2)DHFR (Dihydrofolate reductase)VEGFR-1 (Vascular endothelial growth factor receptor 1)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)TS (Thymidylate synthase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on anlotinib + cisplatin + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anlotinib + cisplatin + pemetrexed.